Nanotherapeutics has been awarded a Department of Defense (DOD) contract to establish Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) capability dedicated to meet the specific needs of the DOD. Nanotherapeutics has assembled a world-class team from throughout the United States to apply new biomanufacturing technologies with existing manufacturing capabilities for small molecule and biologic products that will provide the DOD with the ability to rapidly respond to CBRN events.
Nanotherapeutics’ primary manufacturing goal is to rapidly produce bulk and finished product according to the highest standards. Along with its partners, Nanotherapeutics provides broad/flexible capabilities including:
- A pilot facility for performing optimization of upstream, downstream and formulation functions
- Bulk cGMP manufacturing space for moving prospective MCMs
- Analytical development
- Oversight of small molecule synthesis and release
Nanotherapeutics' manufacturing capabilities include proteins, antibodies, viral vaccines and gene therapy drug products. Nanotherapeutics and its partners are integrated to support clinical development to commercial supply. Nanotherapeutics provides a highly experienced team with expertise from preclinical through FDA licensure in all relevant production platforms.